ConductScience.org, home

Trial · NCT00299104

Adverse events537

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
otherInfusion Related ReactionInjury, poisoning and procedural complicationsPlacebo + Methotrexate53249
otherInfusion Related ReactionInjury, poisoning and procedural complicationsRituximab (0.5 g x 2) + Methotrexate69348
otherInfusion Related ReactionInjury, poisoning and procedural complicationsRituximab (1.0 g x 2) + Methotrexate67263
otherNauseaGastrointestinal disordersPlacebo + Methotrexate42249
otherNauseaGastrointestinal disordersRituximab (0.5 g x 2) + Methotrexate45348
otherNauseaGastrointestinal disordersRituximab (1.0 g x 2) + Methotrexate46263
otherUpper Respiratory Tract InfectionInfections and infestationsPlacebo + Methotrexate44249
otherUpper Respiratory Tract InfectionInfections and infestationsRituximab (0.5 g x 2) + Methotrexate59348
otherUpper Respiratory Tract InfectionInfections and infestationsRituximab (1.0 g x 2) + Methotrexate58263
otherNasopharyngitisInfections and infestationsPlacebo + Methotrexate43249
otherNasopharyngitisInfections and infestationsRituximab (0.5 g x 2) + Methotrexate53348
otherNasopharyngitisInfections and infestationsRituximab (1.0 g x 2) + Methotrexate52263
otherRheumatoid ArthritisMusculoskeletal and connective tissue disordersPlacebo + Methotrexate42249
otherRheumatoid ArthritisMusculoskeletal and connective tissue disordersRituximab (0.5 g x 2) + Methotrexate30348
otherRheumatoid ArthritisMusculoskeletal and connective tissue disordersRituximab (1.0 g x 2) + Methotrexate29263
otherUrinary Tract InfectionInfections and infestationsPlacebo + Methotrexate26249
otherUrinary Tract InfectionInfections and infestationsRituximab (0.5 g x 2) + Methotrexate36348
otherUrinary Tract InfectionInfections and infestationsRituximab (1.0 g x 2) + Methotrexate43263
otherHeadacheNervous system disordersPlacebo + Methotrexate18249
otherHeadacheNervous system disordersRituximab (0.5 g x 2) + Methotrexate17348

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00299104/events